A range of strategies has been explored to enhance the efficacy of adoptive T cells, including the pre-application of ibrutinib [28], coupling with anti-tumor cytokines [29], and the use of immune checkpoint inhibitors such as PD-1 or PD-L1 antibodies [30]. This evidence concerns the gene CD274 and neoplasm.